438 related articles for article (PubMed ID: 18161012)
1. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
Haney M; Hart CL; Vosburg SK; Comer SD; Reed SC; Foltin RW
Psychopharmacology (Berl); 2008 Mar; 197(1):157-68. PubMed ID: 18161012
[TBL] [Abstract][Full Text] [Related]
2. Marijuana withdrawal in humans: effects of oral THC or divalproex.
Haney M; Hart CL; Vosburg SK; Nasser J; Bennett A; Zubaran C; Foltin RW
Neuropsychopharmacology; 2004 Jan; 29(1):158-70. PubMed ID: 14560320
[TBL] [Abstract][Full Text] [Related]
3. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.
Haney M; Cooper ZD; Bedi G; Vosburg SK; Comer SD; Foltin RW
Neuropsychopharmacology; 2013 Jul; 38(8):1557-65. PubMed ID: 23443718
[TBL] [Abstract][Full Text] [Related]
4. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse.
Haney M; Hart CL; Vosburg SK; Comer SD; Reed SC; Cooper ZD; Foltin RW
Psychopharmacology (Berl); 2010 Aug; 211(2):233-44. PubMed ID: 20521030
[TBL] [Abstract][Full Text] [Related]
5. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.
Cooper ZD; Foltin RW; Hart CL; Vosburg SK; Comer SD; Haney M
Addict Biol; 2013 Nov; 18(6):993-1002. PubMed ID: 22741619
[TBL] [Abstract][Full Text] [Related]
6. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
[TBL] [Abstract][Full Text] [Related]
7. Nefazodone decreases anxiety during marijuana withdrawal in humans.
Haney M; Hart CL; Ward AS; Foltin RW
Psychopharmacology (Berl); 2003 Jan; 165(2):157-65. PubMed ID: 12439626
[TBL] [Abstract][Full Text] [Related]
8. Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.
Haney M; Cooper ZD; Bedi G; Herrmann E; Comer SD; Reed SC; Foltin RW; Levin FR
Addict Biol; 2019 Jul; 24(4):707-716. PubMed ID: 29659126
[TBL] [Abstract][Full Text] [Related]
9. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
Herrmann ES; Cooper ZD; Bedi G; Ramesh D; Reed SC; Comer SD; Foltin RW; Haney M
Psychopharmacology (Berl); 2016 Jul; 233(13):2469-78. PubMed ID: 27085870
[TBL] [Abstract][Full Text] [Related]
10. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
Yu E; Miotto K; Akerele E; Montgomery A; Elkashef A; Walsh R; Montoya I; Fischman MW; Collins J; McSherry F; Boardman K; Davies DK; O'Brien CP; Ling W; Kleber H; Herman BH
Drug Alcohol Depend; 2008 Sep; 97(1-2):158-68. PubMed ID: 18508207
[TBL] [Abstract][Full Text] [Related]
11. Bupropion SR worsens mood during marijuana withdrawal in humans.
Haney M; Ward AS; Comer SD; Hart CL; Foltin RW; Fischman MW
Psychopharmacology (Berl); 2001 May; 155(2):171-9. PubMed ID: 11401006
[TBL] [Abstract][Full Text] [Related]
12. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.
Bedi G; Cooper ZD; Haney M
Addict Biol; 2013 Sep; 18(5):872-81. PubMed ID: 22260337
[TBL] [Abstract][Full Text] [Related]
13. Effects of smoked marijuana in healthy and HIV + marijuana smokers.
Haney M
J Clin Pharmacol; 2002 Nov; 42(S1):34S-40S. PubMed ID: 12412834
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Walsh SL; Strain EC; Bigelow GE
Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
[TBL] [Abstract][Full Text] [Related]
15. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha R; Kimmerling A; Doebrick C; Kosten TR
Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
[TBL] [Abstract][Full Text] [Related]
16. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
Gish EC; Miller JL; Honey BL; Johnson PN
Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696
[TBL] [Abstract][Full Text] [Related]
17. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
[TBL] [Abstract][Full Text] [Related]
18. Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers.
Haney M; Bedi G; Cooper ZD; Herrmann ES; Reed SC; Foltin RW; Kingsley PJ; Marnett LJ; Patel S
Addict Biol; 2022 Jul; 27(4):e13183. PubMed ID: 35754107
[TBL] [Abstract][Full Text] [Related]
19. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
[TBL] [Abstract][Full Text] [Related]
20. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans.
Hart CL; Ward AS; Haney M; Comer SD; Foltin RW; Fischman MW
Psychopharmacology (Berl); 2002 Dec; 164(4):407-15. PubMed ID: 12457271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
